Patents matching “recombinant”

WO 2026104630

MÉTHODE DE SÉLECTION DOMINANTE PERMANENTE POUR LA GÉNÉRATION DU VIRUS ANKARA DE LA VACCINE MODIFIÉ RECOMBINANT (MVA)

BAVARIAN NORDIC AS [DK] · Granted May 21, 2026 · Expires May 16, 2046

US 12365930

Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates

Northwestern University · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12364745

Immunogenicity of a CpG-adjuvanted recombinant plague vaccine

The Government of the United States, as represented by the Secretary of the Army · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12344676

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

PRECISION BIOLOGICS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

US 12296004

Recombinant virus with diminished latency and methods of using same

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 13, 2025 · Expires May 8, 2045

US 12292441

Recombinant Acinetobacter baumannii strain AB5075

The Government of the United States, as represented by the Secretary of the Army · Granted May 6, 2025 · Expires May 1, 2045

US 12258372

Recombinant vaccine against Marek's disease and Newcastle disease

The United States of America, as represented by the Secretary of Agriculture · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12233124

Recombinant metapneumovirus f proteins and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 25, 2025 · Expires Feb 20, 2045

US 12209256

System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jan 28, 2025 · Expires Jan 23, 2045

US 12209116

Recombinant human C1 esterase inhibitor and uses thereof

Takeda Pharmaceutical Company Limited · Granted Jan 28, 2025 · Expires Jan 23, 2045

US 12188039

Recombinant adeno-associated viral vector for gene delivery

The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

US 2025002606

Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

BAVARIAN NORDIC AS [DK] · Granted Jan 2, 2025 · Expires Dec 28, 2044

US 12162910

Recombinant gp120 protein with V1-loop deletion

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 10, 2024 · Expires Dec 5, 2044

US 12145968

Recombinant HIV-1 envelope proteins and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 19, 2024 · Expires Nov 14, 2044

US 12128122

Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic

Krystal Biotech, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

US 12128090

Methods of prophylactic treatment using recombinant VWF (rVWF)

Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

US 12121567

Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase

Regents of the University of Minnesota · Granted Oct 22, 2024 · Expires Oct 17, 2044

US 12121571

Recombinant L-asparaginase

Jazz Pharmaceuticals Ireland Limited · Granted Oct 22, 2024 · Expires Oct 17, 2044

US 12108745

Rat model of IgA nephropathy induced with a multimeric recombinant IgA fragment

Northwestern University · Granted Oct 8, 2024 · Expires Oct 3, 2044

US 12091675

Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

Takeda Pharmaceutical Company Limited · Granted Sep 17, 2024 · Expires Sep 12, 2044

US 12091463

Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)

Orionis Biosciences, Inc · Granted Sep 17, 2024 · Expires Sep 12, 2044

WO 2024149832

SARNA (VRP) MODIFIÉ RECOMBINANT POUR VACCIN CONTRE LE CANCER

BAVARIAN NORDIC AS [DK] · Granted Jul 18, 2024 · Expires Jul 13, 2044

US 12029787

Method for generating recombinant poxviruses

UNIVERSITY OF CONNECTICUT · Granted Jul 9, 2024 · Expires Jul 4, 2044

US 12016904

Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF

Takeda Pharmaceutical Company Limited · Granted Jun 25, 2024 · Expires Jun 20, 2044